ArticleFrontiers in neurology2025
The determination of the boundaries and prediction the radicality of glioblastoma resection using MRI and CT perfusion.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dominant Temporo-Basal Glioblastoma with Rapid Progressive Aphasia: Venous-Anchored Maximal Safe Resection and Quantified Language Recovery.Diagnostics (Basel, Switzerland) · 2026Article
- Multiplanar MRI approach to the differential diagnosis of central nervous system tumors and tumor-like lesions in patients with HIV: what radiologists need to know.Frontiers in medicine · 2026Review
- Diagnostic challenges of gliosarcoma: case report of a rare glioblastoma histopathological variant.Frontiers in radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Preoperative identification of diffuse glioma boundaries remains an unsolved problem of modern neurooncology. The main problem is the heterogeneity of the tumor being manifested by simultaneous presence of both contrast-enhancing and non-contrasting but hyperperfused regions on imaging. Perfusion technologies are known to be a reliable tool in identifying areas with intact BBB and increased proliferative activity of vascular endothelium. Aim: The purpose of this study is to evaluate the impact of MRI and CT perfusion data in preoperative planning of surgical resection in order to achieve the maximum volume of cytoreduction and to prolong relapse-free period. Methods: The study included 74 patients with the morphologically and immunohistochemically verified diagnosis of "glioblastoma NOS." The patients were divided into 2 groups depending on the perfusion data and the extent of tumor resection. Group 1 of patients had a surgery with the preoperative use of perfusion techniques and the resection of the contrast-enhancing and hyperperfused portion of the tumor ( Results: The results of the study show that the surgery directed to the resection of contrast-positive and hyperperfused tumor portions has an advantage when compared with surgery aimed at removing only the contrast-enhancing part of the tumor. In group 1, the median relapse-free period was 15 months, while the relapse-free survival in 6 and 12 months was 92 and 55% which exceeded the results in the second group, in which the median was 9 months, and the relapse-free survival in 6 and 12 months was 66 and 9% ( Conclusion: Our study shows that the use of perfusion techniques in preoperative planning of the resection volume has a favorable potential and high diagnostic value. Perfusion tools may be contribute to the most objective assessment of all tumor components. The prolongation of the relapse-free period was achieved by taking into account the factor as the resection of both the contrast-enhanced component and the contrast-negative component with high vascular permeability detected by perfusion techniques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.